CLINICAL STAGE IV CUTANEOUS MELANOMA AJCC V8
Clinical trials for CLINICAL STAGE IV CUTANEOUS MELANOMA AJCC V8 explained in plain language.
Never miss a new study
Get alerted when new CLINICAL STAGE IV CUTANEOUS MELANOMA AJCC V8 trials appear
Sign up with your email to follow new studies for CLINICAL STAGE IV CUTANEOUS MELANOMA AJCC V8, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Custom-Made vaccine aims to train immune system against tough cancers
⭐️ VACCINE ⭐️ Recruiting nowThis early-phase study tests a personalized vaccine made from each patient's unique tumor markers (neo-antigens) to help their immune system fight cancer. It includes up to 25 adults with advanced melanoma, breast cancer, or non-small cell lung cancer that has not responded to st…
Matched conditions: CLINICAL STAGE IV CUTANEOUS MELANOMA AJCC V8
Phase: PHASE1 • Sponsor: Fred Hutchinson Cancer Center • Aim: ⭐️ VACCINE ⭐️
Last updated Jun 16, 2026 12:53 UTC
-
Morning vs. evening: can timing boost melanoma treatment?
Disease control Recruiting nowThis study tests whether giving standard immunotherapy drugs (ipilimumab and nivolumab) in the morning works better than giving them later in the day for people with advanced melanoma that has spread or cannot be removed. About 99 adults with stage IV melanoma will be randomly as…
Matched conditions: CLINICAL STAGE IV CUTANEOUS MELANOMA AJCC V8
Phase: PHASE2 • Sponsor: Emory University • Aim: Disease control
Last updated Jun 16, 2026 22:50 UTC
-
Immune cell attack: new hope for brain metastatic melanoma?
Disease control Recruiting nowThis early-stage trial tests a new treatment for advanced melanoma that has spread to the brain. It combines a chemotherapy drug (temozolomide) with specially grown immune cells (NK cells) from a universal donor. The goal is to see if this combination is safe and can shrink brain…
Matched conditions: CLINICAL STAGE IV CUTANEOUS MELANOMA AJCC V8
Phase: PHASE1, PHASE2 • Sponsor: Kari Kendra • Aim: Disease control
Last updated Jun 16, 2026 12:52 UTC
-
Flu vaccine injected into tumors shows promise against melanoma
Disease control Recruiting nowThis early-stage trial is testing whether injecting a flu vaccine directly into melanoma tumors can help shrink them. The study includes adults with stage I to IV melanoma who have at least one tumor that can be injected. The main goals are to find the safest dose and to see what…
Matched conditions: CLINICAL STAGE IV CUTANEOUS MELANOMA AJCC V8
Phase: PHASE1 • Sponsor: Carlo Contreras • Aim: Disease control
Last updated Jun 16, 2026 12:50 UTC
-
New drug combo targets melanoma brain tumors
Disease control Recruiting nowThis study tests two drugs, binimetinib and encorafenib, in people with advanced melanoma that has spread to the brain. The drugs block enzymes that help cancer cells grow. The goal is to see if this combination can control the disease and improve survival. About 35 adults with a…
Matched conditions: CLINICAL STAGE IV CUTANEOUS MELANOMA AJCC V8
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 16, 2026 12:48 UTC
-
Custom-Made vaccine plus immunotherapy shows promise for advanced cancers
Disease control Recruiting nowThis study tests a personalized vaccine made from a patient's own tumor proteins, given alone or with the immunotherapy drug pembrolizumab, for people with advanced solid tumors (like breast, lung, or skin cancer). The goal is to see if the combination is safe and helps control t…
Matched conditions: CLINICAL STAGE IV CUTANEOUS MELANOMA AJCC V8
Phase: PHASE1, PHASE2 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated Jun 15, 2026 19:09 UTC
-
Spinal immunotherapy injection shows promise for tough brain cancer
Disease control Recruiting nowThis early-stage study tests a drug called nivolumab, given both through a vein and directly into the fluid around the spine, for people with melanoma or lung cancer that has spread to the lining of the brain (leptomeningeal disease). The goal is to find the safest dose and see i…
Matched conditions: CLINICAL STAGE IV CUTANEOUS MELANOMA AJCC V8
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 15, 2026 19:03 UTC
-
Hope for kidney transplant patients with advanced skin cancer: new drug combo aims to fight tumors without losing the donor kidney
Disease control Recruiting nowThis study tests a combination of two immunotherapy drugs (nivolumab and ipilimumab) along with two anti-rejection medications (sirolimus and prednisone) in kidney transplant recipients who have advanced skin cancer that cannot be surgically removed or has spread. The goal is to …
Matched conditions: CLINICAL STAGE IV CUTANEOUS MELANOMA AJCC V8
Phase: PHASE1, PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 15, 2026 19:03 UTC
-
New combo therapy aims to shrink tumors in Hard-to-Treat cancers
Disease control Recruiting nowThis study tests two drugs, cabozantinib and nivolumab, in people with advanced melanoma or head and neck cancer that has spread. The goal is to see if the combination can shrink or stabilize tumors, and whether certain biomarkers in the tumor can predict who responds best. About…
Matched conditions: CLINICAL STAGE IV CUTANEOUS MELANOMA AJCC V8
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 15, 2026 19:02 UTC
-
New drug combo trial hopes to tame advanced cancers
Disease control Recruiting nowThis early-phase study tests a new drug called IACS-6274, given alone or with other medicines, in people with advanced solid tumors (like certain melanomas, ovarian, or uterine cancers). The main goal is to find the safest dose and understand side effects. About 54 adults will ta…
Matched conditions: CLINICAL STAGE IV CUTANEOUS MELANOMA AJCC V8
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 09, 2026 12:10 UTC
-
New hope for melanoma brain metastases: which drug combo works best?
Disease control Recruiting nowThis study tests two different drug combinations in people with a specific type of melanoma (BRAF-V600 mutant) that has spread to the brain. One group gets a targeted therapy plus an immunotherapy, while the other gets two immunotherapies. The goal is to see which approach better…
Matched conditions: CLINICAL STAGE IV CUTANEOUS MELANOMA AJCC V8
Phase: PHASE2 • Sponsor: SWOG Cancer Research Network • Aim: Disease control
Last updated Jun 08, 2026 13:18 UTC
-
Cancer care at home: a new study tests if shots are better than clinic visits
Symptom relief Recruiting nowThis study looks at whether giving the cancer drug nivolumab as a shot at home is as good as getting it in a clinic. It aims to reduce the time, cost, and stress of traveling for treatment. About 50 adults with various advanced cancers will try both settings and report which they…
Matched conditions: CLINICAL STAGE IV CUTANEOUS MELANOMA AJCC V8
Phase: PHASE2 • Sponsor: Mayo Clinic • Aim: Symptom relief
Last updated Jun 16, 2026 22:35 UTC
-
Could a poop transplant fix cancer treatment side effects?
Knowledge-focused Recruiting nowThis study looks at how the bacteria in your gut might cause stomach issues like diarrhea and colitis when you take certain cancer drugs called immune checkpoint inhibitors. Researchers will collect stool, blood, and tissue samples from 800 people with melanoma, lung cancer, or g…
Matched conditions: CLINICAL STAGE IV CUTANEOUS MELANOMA AJCC V8
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Knowledge-focused
Last updated Jun 15, 2026 19:08 UTC
-
Can t cell clues predict immunotherapy success?
Knowledge-focused Recruiting nowThis study looks at how T cells change in people with advanced melanoma, lung, or other cancers during anti-PD-1 immunotherapy. Researchers will measure specific markers in blood samples to see if they can predict treatment response or resistance. The goal is to understand why so…
Matched conditions: CLINICAL STAGE IV CUTANEOUS MELANOMA AJCC V8
Sponsor: Mayo Clinic • Aim: Knowledge-focused
Last updated Jun 15, 2026 18:57 UTC